Discovery of prognostic biomarkers for predicting lung cancer metastasis using microarray and survival data by Hui-Ling Huang et al.
Huang et al. BMC Bioinformatics  (2015) 16:54 
DOI 10.1186/s12859-015-0463-xMETHODOLOGY ARTICLE Open AccessDiscovery of prognostic biomarkers for predicting
lung cancer metastasis using microarray and
survival data
Hui-Ling Huang1,2*, Yu-Chung Wu3, Li-Jen Su4, Yun-Ju Huang5, Phasit Charoenkwan1, Wen-Liang Chen2,
Hua-Chin Lee1,2, William Cheng-Chung Chu6 and Shinn-Ying Ho1,2*Abstract
Background: Few studies have investigated prognostic biomarkers of distant metastases of lung cancer. One of the
central difficulties in identifying biomarkers from microarray data is the availability of only a small number of
samples, which results overtraining. Recently obtained evidence reveals that epithelial–mesenchymal transition
(EMT) of tumor cells causes metastasis, which is detrimental to patients’ survival.
Results: This work proposes a novel optimization approach to discovering EMT-related prognostic biomarkers to
predict the distant metastasis of lung cancer using both microarray and survival data. This weighted objective
function maximizes both the accuracy of prediction of distant metastasis and the area between the disease-free
survival curves of the non-distant and distant metastases. Seventy-eight patients with lung cancer and a follow-up
time of 120 months are used to identify a set of gene markers and an independent cohort of 26 patients is used to
evaluate the identified biomarkers. The medical records of the 78 patients show a significant difference between
the disease-free survival times of the 37 non-distant- and the 41 distant-metastasis patients. The experimental
results thus obtained are as follows. 1) The use of disease-free survival curves can compensate for the shortcoming
of insufficient samples and greatly increase the test accuracy by 11.10%; and 2) the support vector machine with a
set of 17 transcripts, such as CCL16 and CDKN2AIP, can yield a leave-one-out cross-validation accuracy of 93.59%,
a test accuracy of 76.92%, a large disease-free survival area of 74.81%, and a mean survival prediction error of
3.99 months. The identified putative biomarkers are examined using related studies and signaling pathways to
reveal the potential effectiveness of the biomarkers in prospective confirmatory studies.
Conclusions: The proposed new optimization approach to identifying prognostic biomarkers by combining
multiple sources of data (microarray and survival) can facilitate the accurate selection of biomarkers that are most
relevant to the disease while solving the problem of insufficient samples.
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Primary lung cancer is very heterogeneous in its clinical
presentation, histopathology, and treatment response [1].
Differentiating between an occurrence of a new primary
lung cancer and a recurrence of lung cancer is often
difficult. Conventionally, lung cancers have been dividedCorrespondence: hlhuang@mail.nctu.edu.tw; syho@mail.nctu.edu.tw
nstitute of Bioinformatics and Systems Biology, National Chiao Tung
niversity, Hsinchu, Taiwan






Full list of author information is available at the end of the article
© 2015 Huang et al.; licensee BioMed Central.
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.into non-small-cell lung cancer (NSCLC) and small-cell
lung cancer (SCLC). The stage of each cancer is the
most significant predictor of survival. Cancer metastasis
and the emergence of drug resistance are the major
causes of the failure of treatment for lung cancer. Thus,
therapy for lung cancer that takes into account distant
metastasis and drug resistance is an emerging field of re-
search. Prognostic biomarkers are expected to be useful
in predicting the probable course of lung cancer metas-
tases, and they importantly affect the aggressiveness of
therapy. Some new promising strategies for biomarkerThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and mRNA levels, and mass-spectrometry-based pro-
filing at the protein and peptide levels [2]. The com-
bination of multiple biomarkers is generally agreed to
increase diagnostic sensitivity and specificity over the
use of individual markers.
During cancer progression, some tumor cells acquire
new characteristics, such as over-expression of epithelial-
mesenchymal transition (EMT) markers, and undergo pro-
found morphogenetic changes. EMT is a process in which
epithelial cells lose their cell polarity and cell-cell adhesion,
and gain migratory and invasive properties, becoming
mesenchymal cells [3,4]. EMT plays an important role
in cancer progression and provides a new basis for
understanding the progression of carcinoma towards ded-
ifferentiated and more malignant states [3,4]. Additionally,
EMT affects cancer cell invasion, resistance to apoptosis,
and stem cell features [5]. Growth factors [6,7], ligand-
dependent nuclear receptors [8], transcription regulators
[3,9], cytokine [7,10], and kinase [11,12], which are poten-
tial regulators that are related to EMT have been identified
in the literature. Signaling pathways that are activated
by intrinsic or extrinsic stimulation converge on the
transcriptional factors and regulate phenotypic changes of
cancer cells [9].
DNA microarrays perform the simultaneous interrogation
of thousands of genes and provide an opportunity to meas-
ure a tumor from multiple perspectives. Microarray-based
techniques generally provide detailed observations at gene
activities in tumors and generate opportunities for finding
therapeutic targets. As a high-throughput technology at the
molecular level, DNA microarray-based methods have clear
advantages over traditional histological examinations and
have been extensively used in cancer research to predict
more accurately clinical outcomes and potentially improve
patient management. Studies indicate that microarray
techniques greatly facilitate accurate tumor classification
and predicted outcome in terms of, for example, tumor
stage, metastatic status, and patient survival, offering some
hope for personalized medicine [13-15].
Methods for predicting lung cancer metastasis involve
feature (gene) selection and classifier design. Feature selec-
tion identifies a subset of differentially-expressed genes that
are potentially relevant to distinguishing different classes of
samples [16]. One of the central difficulties in investigating
microarray classification and gene selection is the availabil-
ity of only a small number of samples, compared to the
large number of genes in a sample [16]. Hierarchical clus-
tering [17] is one of the most commonly used approaches
in microarray studies. However, hierarchical clustering
(or any purely correlative technique) cannot alone provide
a rational biological basis for disease classification [18].
Generally, univariate analysis is conducted to reduce feature
size and, then, a support vector machine (SVM) [19] ormaximum likelihood classification [20] with an effective fea-
ture selection method is used to identify a small set of in-
formative genes. The most challenging task is to avoid
overfitting a small number of samples, resulting in the poor
performance of independent tests.
In this work, the medical records of 78 patients with
lung cancer and a follow-up time of 120 months reveal
significant difference between the disease-free survival
times of the 37 non-distant- and the 41 distant-
metastasis patients. To solve the problem of insuffi-
cient samples, this work proposes a novel optimization
approach to discovering EMT-related prognostic bio-
markers for predicting the distant metastasis of lung
cancer using both microarray and survival data. The
proposed optimal gene selection method incorporates
gene expression profiles and their corresponding disease-
free survival curves of patients to design a fitness function
for using an intelligent genetic algorithm [21]. The set of
78 samples is used to identify a set of gene markers and an
independent cohort of 26 samples is used to evaluate the
identified biomarkers. The experimental results show that
disease-free survival curves can compensate for the insuf-
ficient samples and the SVM with a set of 17 transcripts
can yield high prediction accuracies of distant metastasis
and disease-free survival time. The putative biomarkers
for predicting the distant metastasis of lung cancer are




RNA isolation and microarray platform
Illumina Sentrix-6 Whole-Genome Expression BeadChips
are relatively new microarray platforms, that have been
used in many microarray studies in the past few years
[22]. Physically, each Sentrix-6 BeadChip consists of 12
equally-spaced strips of beads. Each pair of adjacent strips
comprises a single microarray and is hybridized with a sin-
gle RNA sample [22]. The used microarray is Illumina of
HumanWG-6 BeadChip Kit Support. Fresh-frozen
specimens were removed from liquid nitrogen and ho-
mogenized using TissuLyzer in RLT buffer of RNeasy
isolation kit, both from Qiagen. Total RNA was ex-
tracted from fresh-frozen tumors followed the manu-
facturer’s suggestion, purified by RNeasy mini kit, and
checked by NanoDrop spectrophotometer and Agilent
Bioanalyzer for quantity and quality. Biotin labeled
cRNA was prepared from Illumina TotalPrepTM RNA
amplification kit, Life Technologies. One and half ug
cRNA was hybridized to the Illumina Multi-sample
Human WG-6 v3.0 chip according to manufacturer’s
instructions. Globe normalization was used to normalize
for signal intensity of chips. This microarray of a sample
has 48,803 transcripts.
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The dataset of 78 lung cancer samples, comprising 37
non-distant- and 41 distant-metastasis samples as well
as their corresponding disease-free survival time, comes
from Taipei Veterans General Hospital (TVGH) in
Taiwan. This work developed prognostic models using
these 78 samples. To evaluate the potential of putative
biomarkers and the gene-discovery method for identify-
ing a small set of genes that can be used to predict dis-
tant metastasis of lung cancer, a cohort of 26 samples,
comprising 6 non-distant- and 20 distant-metastasis
patients of TVGH, is utilized as an independent test
dataset. This study as well as the tissue procurement
protocol were approved by the Institutional Review
Board of TVGH (VGHIRB No. 2013-04-015 AC), and
written informed consent was obtained from all patients.
The datasets of 78 and 26 samples consisting of micro-
array data and disease-free survival time that the pa-
tient identifiers have been removed are given in
Additional file 1: Table S1 and Additional file 2: Table
S2, respectively.
Characteristics of cohorts
Patient survival is a major clinical parameter that is used
to evaluate the efficacy of a particular therapy. Disease-
free survival, used herein, is defined as the time between
surgery and the occurrence of an event (death or distant
metastasis). The censored data are that when the event
did not occur, and the survival time is that between sur-
gery and the last follow-up date. Figure 1 shows statistics
concerning disease-free survival times for 78 lung cancer
patients with a follow-up time of 120 months. The mean
times of disease-free survival for non-distant and distant
metastasis are 73.08 and 14.02 months, respectively. A
t-test with p-value = 7.99E-22 reveals a significant dif-
ference (p < 0.001) between the disease-free survivalFigure 1 Disease-free survival times for 78 lung cancer patients with
survival for non-distant and distant metastasis are 73.08 and 14.02 months,
The p-value of t-test is 7.99E-22 (p < 0.001) suggesting that distant metastatimes of the 37 non-distant- and the 41 distant-
metastasis patients. The result suggests that distant
metastasis is strongly correlated to patients’ survival.
Some characteristics of these 78 patients were summa-
rized in Table 1. From the results of Fisher’s exact test,
there was no significant association between distant
metastasis and the interested factors such as age, sex,
smoking, tumor size, pN and pM status, histologic
type, and differentiation (p > 0.05). Notably, there was
a strong association between distant metastasis and
pathologic stage (p = 3.0E-5).
EMT-related transcripts
Ingenuity Knowledge Base (IKB; http://www.ingenuity.
com) is a repository of biological interactions and
functional annotations that are created from millions
of individually modeled relationships among proteins,
genes, complexes, cells, tissues, metabolites, drugs, and
diseases. IKB provides comprehensive, species-specific
knowledge about the function and regulation of genes, tis-
sue and cell line expression patterns, clinical biomarkers,
subcellular locations, mutations, and disease associations.
First, EMT-related genes annotated as “growth factor”,
“ligand-dependent nuclear receptor”, “transcription
regulator”, “cytokine”, or “kinase” in the IKB are iden-
tified. As a result, 4,314 transcripts are identified in the
HumanWG-6 microarray data, comprising 233 transcripts
of growth factor, 103 transcripts of ligand-dependent nu-
clear receptor, 2,465 transcripts of transcription regulator,
276 transcripts of cytokine, and 1,237 transcripts of kinase.
Second, univariate t-test analysis is used to calculate the
p-values of individual transcripts between two classes. The
genes with a very small p-value are useful in predicting
distant metastasis. There are 474 top-ranked transcripts
according to the p-value selected from the 4,314 EMT-
related transcripts. The training dataset of 78 samples witha follow-up time of 120 months. (A) The mean times of disease-free
respectively. (B) The box plots of non-distant and distant metastasis.
sis is highly correlated to patients’ survival.







≧65 49 63 25 24 0.64
<65 29 37 17 12
Sex
Male 56 72 28 28 0.32
Female 22 28 14 8
Smoking index
≧20 pack-year 35 45 17 18 0.49
<20 pack-year 43 55 25 18
Histologic type
Squamous cell 25 32 11 14 0.46b
Adenocarcinoma 46 59 25 21
Large cell 5 6 4 1
Other cell type 2 3 2 0
Differentiation
Well 5 6 1 4
Moderate 51 65 28 23 0.80b
Poor 22 28 13 9
Tumor size
≧5 cm 18 23 11 7 0.59
<5 cm 59 76 31 28
pN status
Positive 54 69 25 29 0.09
Negative 25 32 17 7
pM status
Positive 5 6 5 0 0.20
Negative 73 94 37 36
Pathologic stage
Stage I 36 46 10 26 3.0E-5c
Stage II 11 14 7 4
Stage III 26 33 20 6
Stage IV 5 6 5 0
aThe two-sided p-values were calculated by Fisher's exact test.
bThe p-values were calculated using the two variables with the largest
numbers of patients.
cThe p-value was calculated to measure the association between two variables
(Stage I and Stages II, III and IV).
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set of prognostic biomarkers that is predictive of the
distant metastasis of lung cancer.
Methods
Disease-free survival area
The Kaplan-Meier survival curves reveal a significant
difference between the survival times of patients in thetwo classes. The disease-free survival area is calculated
between the two survival curves from zero to the
maximum disease-free survival time (117 months in this
work). The disease-free survival area is represented as a
percentage, which is the ratio of this area to the
maximum area. The gene set with a large disease-free
survival area is expected to have a strong ability to
distinguish a non-distant metastasis from a distant
metastasis of lung cancer.
Fitness function
Microarray data contain valuable information about a
huge gene set but often suffer from a small number of
available samples. In the design of classifiers with gene
selection, there exist numerous candidate sets of genes
that can achieve high training accuracies for predicting
distant metastasis. However, most of the candidate gene
sets have relatively low accuracies of independent tests
that result in overtraining. The right sets of biomarkers
should have high prediction accuracies for both training
and test datasets. To cope with the overtraining prob-
lem, it is essential to identify the right sets of biomarkers
by discarding the gene sets of overtraining. Recently ob-
tained evidence reveals that distant metastasis from lung
cancer is detrimental to patients’ survival [23]. Moreover,
Figure 1 suggests that distant metastasis is strongly
related to patients’ survival. Thus, it is hypothesized that
the right set of biomarkers can also be used to effectively
predict patients’ survival. This work proposes a hybrid
approach that uses two kinds of resources, microarray
data and the disease-free survival data, to identify a set
of biomarkers.
The fitness function provides the only means by which
genetic algorithms (GAs) optimize all system parameters
that are encoded in a GA-chromosome. The three ob-
jectives of designing the predictor of lung cancer me-
tastasis and discovering a set of genes using GA-based
optimization methods are as follows. The first objective is
to maximize the classification accuracy (denoted as Acc)
of the SVM classifier; the second is to maximize the
disease-free survival area (denoted as Asurv), and the last
is to identify a small set of informative genes. The values
of Acc and Asurv are in the range [0, 1]. The two max-
imum objectives without conflicting each other can be
combined into a weighted objective function f(G) as
follows.
Maxf Gð Þ ¼ w Accþ 1–wð Þ  Asurv ð1Þ
where w denotes a positive weight in the range [0, 1]
which is determined according to the preferences for in-
dividual objectives, and G denotes the selected gene set.
Generally, maximizing f(G) is the major objective and
the number of selected genes is restricted within a
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section). If w = 1.0, then the fitness function degenerates
to the conventional one that uses no clinical outcome
(disease-free survival curve). The fitness function using
the overall accuracy Acc is suitable for balanced datasets
(almost equal populations of metastatic positive and
negative samples). When applying to imbalanced data-
sets, random over-sampling methods such as SMOTE
which is short for Synthetic Minority Over-sampling
Technique [24] can be used to adjust these datasets to
balanced datasets.
Gene selection using IBCGA
Selecting a minimal number of informative genes while
maximizing the prediction performance of distant me-
tastasis is a bi-objective 0/1 combinatorial optimization
problem. This work propose a novel method for identi-
fying a small number m of informative genes from a
large number n of candidate genes for prediction and
biomarker discovery based on an inheritable bi-objective
combinatorial genetic algorithm (IBCGA) [25] with
SVM classifiers. IBCGA has been previously used to
identify a small set of properties from 531 physicochemi-
cal properties for predicting the immunogenicity of
MHC class I binding peptides [26]. Feature selection is a
combinatorial optimization problem C(n, m) with a
huge search space of size C(n, m) = n!/(m!(n-m)!)). The
IBCGA uses an intelligent genetic algorithm (IGA) [21]
with an inheritance mechanism [25] to search efficiently
for the solutions Sr to C(n, r) and Sr+1 to C(n, r + 1) by
inheriting the good solution Sr. IGA that is based on or-
thogonal experimental design uses a divide-and-conquer
strategy and a systematic reasoning method rather than
a conventional generate-and-go method to solve effi-
ciently the large-scale combinatorial optimization prob-
lem. The SVM-based training model uses the prediction
performance of leave-one-out cross-validation (LOOCV)
as the fitness function in using IBCGA with the whole
training set.
The input for the SVM-based model design procedure
is a training dataset that is composed of two classes
(distant and non-distant metastases). The output of the
procedure includes a set of m selected transcripts and
an SVM classifier with associated parameter settings of γ
and C. A radial basis kernel function exp(−γ ||xi - xj||
2)
is adopted, where xi and xj are training samples, and γ is
a kernel parameter. In this work, γ ∈{2−7, 2−6, …, 28} and
C∈{2−7, 2−6, …, 28}. Each sample is represented using an
n-dimensional feature vector P = [p1, p2, …, pn]. In this
work, n = 474. The IGA-chromosome consists of n bin-
ary IGA-genes fi to select features and two 4-bit genes
for encoding γ and C. The corresponding feature pi (the
i-th transcript) is excluded from the SVM classifier if
fi = 0, and is included if fi = 1. Let m be the sum of fi.The IBCGA with the fitness function f(G) that uses
LOOCV can simultaneously obtain a set of solutions, Sr,
where r = rstart, rstart + 1, …, rend in a single run. In this
work, the parameter settings are rstart =10, rend =30,
Npop =60, pc =0.8, pm =0.05, and Gmax =60. The cus-
tomized IBCGA for transcript selection is given below.
Step 1 (Initiation) Randomly generate an initial popu-
lation of Npop individuals. All n binary genes fi have r 1 s
and n-r 0 s where r = rstart.
Step 2 (Evaluation) Evaluate the fitness values of all
individuals using f(G).
Step 3 (Selection) Use a conventional method of
tournament selection that selects the winner from two
randomly selected individuals to generate a mating pool.
Step 4 (Crossover) Select pc ·Npop parents from the
mating pool to perform orthogonal array crossover [25]
on selected pairs of parents where pc is the probability
of crossover operations.
Step 5 (Mutation) Apply a conventional mutation
operator to the randomly selected pm ·Npop individuals
(except the best individual) in the new population where
pm is the probability of mutation operations.
Step 6 (Termination test) If the stopping condition
(reaching Gmax generations) for obtaining the solutions
Sr is satisfied, then output the best individual as Sr.
Otherwise, go to Step 2.
Step 7 (Inheritance) If r < rend, then randomly change
one bit in the binary genes fi for each individual from 0
to 1; increase r by one, and go to Step 2.
Step 8 (Non-deterministic) Perform Steps 1–7 for R
(=30 in this work) independent runs and obtain the best
of the R solutions. The best solution can be determined
by considering the most accurate one (Sa) with the high-
est fitness value or the robust one (Sb) with the highest
score of appearance [27]. The appearance score con-
siders both the fitness value as well as the mean number
of times for individual genes selected in the R runs.
Notably, all genetic algorithms search for globally opti-
mal solutions but their outputs are non-deterministic
because of randomization. Therefore, the common ap-
proach to solving with the non-deterministic problem is
to perform a number of independent runs to evaluate
the final answer. In this work, the answers obtained in
all R runs are utilized efficiently, as described in the next
section.
Gene selection using a sequential backward selection
method
An IGA-based gene selection method with SVM (known
as ESVM) [19] can obtain a high prediction accuracy of
96.88% with a mean number of 10.0 to select genes from
11 benchmark datasets concerning various cancers using
10-fold cross-validation (10-CV). For two two-class
tumor datasets, ESVM yields a mean number of 4.65
Table 2 Accuracies of the independent test for various
weights in the fitness function
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gene selection method uses a maximum likelihood
(MLHD) classifier [20] to select a minimal number of
relevant genes for accurate classification of tumor
samples. The experimental results show that the hybrid
method IGA/MLHD outperforms existing methods in
terms of the number of selected genes (9.86 on average),
classification accuracy (mean accuracy of 96.20%), and
robustness of the selected genes based on 11 human
cancer-related gene expression datasets.
In this work, the IBCGA that is based on IGA with an
SVM selects a small set of genes that are relevant to the
distant metastasis of lung cancer while maximizing the
fitness function. Since the number of samples (78) is
very small, the IBCGA can identify a very small number
m of genes and obtain a very high training accuracy with
m < 10. However, a very small number of genes can
provide a very high training accuracy (either LOOCV or
10-CV) but the independent accuracy is not always satis-
factory owing to overtraining. Moreover, a feasible set
of biomarkers for yielding the high tumor prediction
accuracy on an independent test dataset often has more
than 10 genes. Therefore, this work proposes a novel
methodological approach to alleviating the overtraining
problem in two ways: 1) by utilizing additional clinical
data, i.e. the disease-free survival curve, and 2) using a
sequential backward selection (SBS) method to select
the best set of transcripts from all of the selected tran-
scripts of the R = 30 runs of the IBCGA. For each run,
the IBCGA selects at least 10 transcripts (rstart = 10).
Sequential backward selection starts from the full set of
the 30 transcripts with the highest appearance times,
and sequentially removes transcript x from G (called the
G-x set) that results in the smallest decrease of the value
of the objective function f(G-x). Notably, the removal of
a feature may actually increase the value of the objective
function such that f(G-x) > f(G).Results and discussion
Performance evaluation with various weights
To determine the best value of the weight w and
prevent overtraining in the subsequent design of gene
selection methods, all the 78 samples are randomly
divided into five groups, of which four are used as a
training set and the other serves as an independent
test set. Each group of samples serves as a test set in
turn. Four experiments with w values of 1.0, 0.8, 0.5,
and 0.2 are conducted. Table 2 shows the mean accur-
acies of the independent test for various weights. The
results reveal that the best performance is achieved
using w = 0.8 with a test accuracy of 74.82%. The con-
ventional method has an accuracy of 61.62% when the
disease-free survival area is not used (w = 1.0). Theadditional use of a survival curve can compensate for
the shortcomings of insufficient microarray samples
and improve the test accuracy 13.20%.
Identifying a gene set using IBCGA and sequential
backward selection
The IBCGA identifies a small number m of transcripts
from n = 474 candidate transcripts while maximizing the
fitness function f(G). The results show that m = 10 has a
very high value of f(G). The IBCGA with R = 30 runs
yields 30 sets of transcripts. The most accurate solution
Sa and the most robust solution Sb are recorded. The
number of appearances of each selected transcript in the
30 runs is recorded. Table 3 lists statistical results con-
cerning the number of appearances for the 30 transcripts
with the highest appearance frequency. The genes with
rank 1 are FBJ murine osteosarcoma viral oncogene
homolog B (FOSB) and microtubule associated serine/
threonine kinase 1 (MAST1), which were selected 12
times. The gene forkhead box E1 (FOXE1) has two tran-
scripts with ID numbers 6250309 and 3450692, named
FOXE1-1 and FOXE1-2, at ranks nine and 13, respect-
ively. Similarly, the gene protein kinase C beta (PRKCB1)
has two transcripts with ID numbers 3460564 and
5090563, named PRKCB1-1 and PRKCB1-2, at ranks 23
and 27, respectively. The set of 30 transcripts was used
in the sequential backward selection (SBS) method for
further identifying a set of prognostic biomarkers that
are effective and stable in predicting lung cancer metas-
tasis. Figure 2 shows the results of the SBS method for
w = 0.8 and 1.0. Table 4 shows the performance of the
IBCGA and SBS methods for w = 0.8 and 1.0.
From Figure 2, the SBS method with 17 transcripts
and w = 0.8 has the largest disease-free survival area
(Asurv = 74.81%) and prediction accuracy (Acc = 93.59%).
The largest Asurv is 70.92% and Acc = 91.03% when a set
of 15 transcripts was adopted for w = 1.0. From Table 4,
the Sa solution has a set of 10 transcripts and is associ-
ated with a performance of Acc = 95.95% and Asurv =
70.01% for w = 0.8. The Sb solution has a set of 10 tran-
scripts and is associated with a performance of Acc =
92.02% and Asurv = 63.81% for w = 0.8. Consider that 1)
the 30 transcripts with high frequency are selected; 2)
the test accuracy of w = 0.8 is higher than that of w = 1.0;
and 3) the set of 17 transcripts yields the largest disease-
Table 3 The 30 top-ranked transcripts in terms of selected
times from 30 runs
Rank Transcript Frequency Rank Transcript Frequency
1 FOSB 12 16 CDKL5 3
2 MAST1 12 17 DCK 3
3 CCL15 8 18 KLF12 3
4 MAK 6 19 ZAP70 3
5 SF1 5 20 BACH2 3
6 HDAC9 5 21 YSK4 3
7 YSK4 4 22 ELF5 3
8 EDN1 4 23 PRKCB1-1 2
9 FOXE1-1 4 24 CEP110 2
10 GLI3 4 25 HS.541237 2
11 CDKN2AIP 4 26 KLF6 2
12 CREG1 3 27 PRKCB1-2 2
13 FOXE1-2 3 28 MAK 2
14 CSNK1A1 3 29 CCL16 2
15 TUB 3 30 IL23A 2
Figure 2 The prediction accuracy and disease-free survival area obtai
(B) w = 1.0.
Table 4 The performance of the IBCGA and sequential
backward selection (SBS) methods
Method w = 0.8 w = 0.8 w = 1.0 w = 1.0
Acc (%) Asurv (%) Acc (%) Asurv (%)
IBCGA (Sa) 95.95 70.01 97.43 69.21
IBCGA (Sb) 92.02 63.81 94.73 66.91
SBS 93.59 74.81 91.03 70.92
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transcripts of the 16 genes obtained using the SBS
method with w = 0.8. The 16 genes regarded as a candi-
date set of biomarkers (the 16-gene set) can be further
analyzed.
Analyzing identified 16-gene set
To investigate the abilities of individual genes to predict
distant metastasis, the rankings by classification ability,
disease-free survival area, and p-value using the training
dataset are analyzed. The classification ability ranking is
derived according to the classification accuracy using a
single gene and the SVM classifier with a parameter set-
ting using a grid search method. Table 5 lists the rank-
ings of classification ability, disease-free survival area,ned using the sequence backward selection method. (A) w = 0.8
Table 5 The 17 transcripts obtained by the sequence








CCL16 74.36 (1) 43.58 (2) 5
GLI3 71.79 (2) 34.43 (6) 15
TUB 71.79 (3) 35.71 (4) 13
PRKCB1-1 70.51 (4) 34.51 (5) 3
ZAP70 67.95 (5) 29.53 (8) 14
ELF5 67.95 (6) 26.70 (10) 17
EDN1 66.67 (7) 31.09 (7) 9
SF1 66.67 (8) 25.87 (11) 8
CREG1 66.67 (9) 23.40 (14) 2
MAST1 65.38 (10) 23.71 (13) 12
CSNK1A1 64.10 (11) 24.95 (12) 11
HDAC9 64.10 (12) 27.78 (9) 10
MAK 62.82 (13) 38.76 (3) 4
CCL15 61.54 (14) 22.94 (15) 6
PRKCB1-2 61.54 (15) 16.73 (17) 1
CDKN2AIP 61.54 (16) 46.00 (1) 16
FOXE1-1 60.26 (17) 19.60 (16) 7
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Table 5 reveals that the distributions of rankings for the
three metrics are diverse. All of the p-values of the 17
transcripts are very small so a comparison of p-value
ranking is not meaningful. The Person correlation coeffi-
cient between the ranks based on the two metrics (ac-
curacy and survival area) is not very high (R = 0.4755).
The gene chemokine (C-C motif ) ligand 16 (CCL16)
provides the highest classification accuracy (74.36%) and
the second largest area of disease-free survival (43.58%).
The gene CDKN2A-interacting protein (CDKN2AIP) has
a disease-free survival area of 46.00% (rank 1) and a
classification accuracy of 61.54% (rank 16). The signifi-
cant variation among the rankings of genes based on the
three metrics is discussed below.
The effective discrimination between distant and non-
distant metastases can be achieved using a set of interacted
genes that are involved in various signaling pathways, rather
than a set of mutually independent genes. The LOOCV ac-
curacy of 93.59% that is obtained using the 16-gene set sub-
stantially exceeds that obtained using a single gene. On the
other hand, when all of the 17 transcripts are used to pre-
dict distant metastasis, the disease-free survival area (Asurv)
is 74.81%, which is very close to the real area of 73.21%.
Moreover, this area (74.81%) is much larger than that ob-
tained using a single gene. The expression level of individ-
ual genes using the microarray technique cannot be used
reliably to discriminate between samples of distant andnon-distant metastases. Several factors determine patient
survival, including gene expression and the nature of the
therapy. Therefore, survival curve provides valuable infor-
mation, but care must be taken in using the survival curves
of individual genes. In brief, the rankings of individual
genes for the three metrics based on univariate analysis can
be used in initial screening in coarse-to-fine gene selection.
In this work, the discovery of biomarkers in the fine stage
takes into account a set of genes by combining both the
classification ability and disease-free survival area.
Numerous prediction methods discover biomarkers by
searching for a set of genes that can provide highly ac-
curate performance of LOOCV or 10-CV [19,20]. Many
sets may comprise a small number of genes that can
achieve the same goal. The highest LOOCV accuracy
that can be achieved using SVM with ten genes without
considering the disease-free survival curves is 97.43%
(w = 1.0, Table 4). The proposed method of applying SBS
to a combination of promising gene sets aims to identify
a set of reliable biomarkers for predicting distant metas-
tasis. Notably, some genes in the set of 30 transcripts
(Table 3) but not in the identified 16-gene set may also
be potential biomarkers.
Evaluation of biomarkers using an independent cohort
To evaluate generalizability of the identified gene sets,
an independent cohort of 26 samples was utilized.
Table 6 shows the performance of the IBCGA and the
SBS methods by performing 30 runs on the 26 test
samples. The training accuracies for w = 1.0 and 0.8 are
88.80% and 88.88%, respectively, which are very close to
each other. However, the test accuracies for w = 1.0 and
0.8 are 50.41% and 61.08%, respectively. The test accur-
acy obtained using disease-free survival curves (w = 0.8)
is larger than that obtained using no survival curve (w =
1.0) that is improved by 10.67%. The test accuracies of
the SBS method for w = 1.0 and 0.8 are 53.84% and
65.38%, respectively. The improvement in the test accur-
acy is 11.54%. The improvement in the mean test accur-
acy using the disease-free survival curves is 11.10%. The
results also reveal that the SBS method that includes the
IBCGA outperforms the IBCGA method alone for both
w = 1.0 and 0.8.
The SBS method with w = 0.8 is the best method,
yielding an LOOCV accuracy of 93.59% and a predicted
disease-free survival area of 74.81%, which is very close
to the real disease-free survival area of 73.21%. The ac-
curacy of the independent test using an SVM classifier
with 17 transcripts is 65.38%. The SVM ensemble of 30
SVM classifiers of which each uses five transcripts that
are randomly selected from the 17 transcripts can yield
the test accuracy of 76.92%. The intractable problem of
overtraining has been alleviated by the additional use of
survival curves in the proposed optimization method.
Table 6 The test accuracies of the IBCGA and sequence
backward selection (SBS) methods from 30 runs
Method No. of features Training Acc (%) Test Acc (%)
IBCGA (w = 1.0) 10 88.80 ± 3.92 50.41 ± 6.56
IBCGA (w = 0.8) 10 88.88 ± 3.27 61.08 ± 7.35
SBS (w = 1.0) 15 91.03 53.84 (14/26)
SBS (w = 0.8) 17 93.59 65.38 (17/26)
SVM ensemble 17 93.59 76.92 (20/26)
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select a putative set of biomarkers. Increase of the
number of samples can further mitigate the overtraining
problem.
Performance comparison of various gene sets
Table 7 shows the type of regulator and location of its
protein product, as well as the related cancer genes in
the 16-gene set. The 16 genes are as follows: 1) endothe-
lin 1 (EDN1), 2) casein kinase 1, alpha 1 (CSNK1A1), 3)Table 7 The type of regulator and location of its protein
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apoptosischemokine (C-C motif ) ligand 15 (CCL15), 4) splicing
factor 1 (SF1), 5) gene protein kinase C beta (PRKCB1),
6) microtubule-associated serine/threonine protein kin-
ase 1 (MAST1), 7) zeta-chain associated protein kinase
70 kDa (ZAP70), 8) chemokine (C-C motif ) ligand 16
(CCL16), 9) E74-like factor 5 (ELF5), 10) CDKN2A-
interacting protein (CDKN2AIP), 11) histone deacetylase
9 (HDAC9), 12) GLI family zinc finger 3 (GLI3), 13)
forkhead box E1 (FOXE1), 14) male germ cell-associated
kinase (MAK), 15) tubby protein homolog (TUB), and 16)
cellular repressor of E1A-stimulated genes 1 (CREG1).
The 16-gene set can be categorized into two subsets. One
subset has five known lung-cancer-related genes (named
5-gene set), including EDN1, CSNK1A1, CCL15, SF1 and
PRKCB1. The other subset (11-gene set) consists of nine
cancer-related genes and two potential biomarkers (TUB
and CREG1).
A number of lung cancer-related genes in the litera-
ture are considered for further comparison and analysis.
Since EMT is known to be involved in tumor malig-
nancy, some mesenchymal-related genes of gastric
cancer, including WNT5A, CDH2, PDGFRB, EDNRA,
ROBO1, ROR2, and MEF2C that are activated by an
EMT regulator, are also examined [28]. Table 8 pre-
sents the 32 genes and their relevant papers [28-39].
The same sequence backward selection (SBS) method
is applied to the 32-gene set, yielding a set of nine
genes that can be used to accurately predict distant
metastasis of lung cancer. The 9-gene set consists of
MEF2C, MMP-2, ID2, CDH2, WNT5A, CDH1, TGFB1,
MMP-9, and TWIST2. Notably, cigarette smoke induces
WNT5A-coupled PKC activity during lung carcinogenesis,
which causes Akt activity and anti-apoptosis in lungTable 8 The 32 lung cancer-related genes and their
relevant papers
No. Gene name Paper
1 CDH2, PDGFRB, ROBO1, ROR2,
MEF2C, WNT5A, EDNRA
Ohta et al. [28]
2 ZEB1, ZEB2, CDS1, ST14, FGFR1,
TWIST1, TWIST2, TGFB1
Gemmill et al. [29]
3 VIM, MUC1, S100A4, FOXQ1 Feng et al. [30]
4 ID2, TGFB1 Yoshikawa et al. [31]
5 SNAI1, MMP-9, MMP-7, MMP-2,
S100A4, TGFB1
Ward et al. [32]
6 HMGA2, TTF1 Qi et al. [33]
7 SYK Singh et al. [34]
8 TYRO3, AXL, PDGFRB Thomson et al. [35]
9 SIP1, ZEB1 Takeyama et al. [36]
10 TCF4 Xiang et al. [37]
11 SNAI1, TGFB1 Matsuno et al. [38]
12 CDH1, TWIST1 Pallier et al. [39]
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andMEF2C were also selected into the 9-gene set.
Table 9 presents performance comparisons of various
gene sets in terms of the prediction accuracy. The train-
ing accuracy, disease-free survival area, and independent
test accuracy obtained using the 32-gene set are 65.38%,
34.47%, and 50.00%, respectively. The performance of
the 32-gene set is not good, especially for the independ-
ent test. This lung cancer-related gene set is not de-
signed especially to predict distant metastasis of lung
cancer. The 9-gene set yields a training accuracy of
73.07%, a disease-free survival area of 55.70%, and an in-
dependent test accuracy of 80.76%. As a result, the 9-
gene set that is obtained using the SBS method is more
effective in identifying the distant metastasis than is the
32-gene set, and is worthy of further validation.
The 16-gene set for predicting distant metastasis is
identified using microarray and survival data at the same
time. The test accuracy is 76.92% for the 16-gene set
using an SVM ensemble classifier. To analyze the 16-
gene set further, its two subsets (5- and 11-gene sets)
are independently evaluated using the same prediction
method as that used to evaluate the 16-gene set, and the
results are shown in Table 9. The training accuracy,
disease-free survival area, and independent test accuracy
achieved using the 5-gene set with six transcripts are
78.25%, 52.33%, and 76.92%, respectively, which are
close to those achieved using the 9-gene set. The 11-
gene set of EMT and cancer-related genes has a higher
training accuracy of 87.18%, which is nearly equal to the
survival area of 53.37%, and has a smaller test accuracy
of 69.23% than the 5-gene set. To compare individual
genes in terms of their prediction performance, three
representative genes in the 16-gene set were selected.









65.38 34.47 50.00 (13/26)
9-gene (SBS from
the 32-gene set)
73.07 55.70 80.76 (21/26)
16-gene (EMT related,
SVM ensemble)
93.59 74.81 76.92 (20/26)
11-gene (EMT and
cancer related)
87.18 53.37 69.23 (18/26)
5-gene (EMT and lung
cancer related)
78.25 52.33 76.92 (20/26)
1-gene (CCL16,
maximum Acc)
74.36 43.58 57.69 (15/26)
1-gene (CDKN2AIP,
maximum Asurv)
61.54 46.00 76.92 (20/26)
The value of Asurv is 73.21% for real classes of samples in the training dataset.disease-free survival area are CCL16 (74.36%) and
CDKN2AIP (46.00%), respectively. Figure 3 plots the
Kaplan-Meier survival curves and their corresponding
disease-free survival areas for real and predicted
classes obtained using various gene sets.
The large disease-free survival area (74.81%) of pre-
dicted classes, obtained using the 16-gene set, is remark-
ably very close to that of the real classes (73.21%). To
investigate the ability of this set to predict patient’s
disease-free survival time, the support vector regression
in the LIBSVM [41] is used to establish a survival pre-
diction model. Figure 4 shows that, in the estimate of
the disease-free survival time, the correlation coefficient
between the real and predicted disease-free survival
times is R = 0.9672. The mean survival prediction error
is 3.99 months. This result reveals that the 16-gene set is
also effective in predicting disease-free survival times of
patients.
Examination of the 16 putative biomarkers
The 16 putative biomarkers herein are examined with
reference to the relevant papers. Five of the 16 genes
have been shown to be related to lung cancer progres-
sion. Decreased expression of EDN1 has been reported
in primary lung cancers, possibly owing to the high
methylation in the CpG island of its intron 1 and exon 2
junction [42]. Overexpressions of EDN1 and EDNRA
were already reported as being associated with impaired
survival in human breast cancer [43]. Expression ana-
lysis reveals that hypoxia-induced lung cancer related-
biomarkers HIF and its modulating proteins, including
CSNK1A1, are significantly down-regulated [44]. The
CCL15 level correlates with response to combination
therapy with erlotinib and celecoxib in patients with
NSCLC [45]. Chemokine CCL15 is the most signifi-
cant marker that is associated with increased odds of
short survival [46]. Splicing factor SF1 participates in the
ATP-dependent formation of the spliceosome complex
[47]. Down-regulation of the oncogenic serine/arginine-
rich splicing factor 1 (SF1) leads to the skipping of an exon
that is overexpressed in primary lung tumors [48]. PRKCB
belongs to a family of serine/threonine-specific kinases
and is predominantly activated by diacylglycerol, calcium,
and phorbol ester. The two splice-variants are called
PRKCB1 and PRKCB2. PRKCB1 exists in lung cancer cell
lines in the context of enzastaurin-induced proliferation
and kinase inhibition, determined by using exon sequen-
cing, immunoblotting, and cytotoxicity assays in NSCLC
and SCLC cell lines [49].
The nine cancer-related genes are briefly described
below. Breast cancer cell lines that harbor Notch gene
rearrangements are uniquely sensitive to the inhibition
of Notch signaling, and the overexpression of MAST1 or
MAST2 gene fusions has a proliferative effect [50]. The
Figure 3 The disease-free survival areas of various gene sets using Kaplan-Meier survival curves. There are 37 non-distant- (in blue) and
41 distant-metastasis samples (in red). (A) real class (73.21%), (B) 16-gene set (74.81%), (C) 11-gene set (53.37%), (D) 5-gene set (52.33%), (E) CCL16
(43.58%) and (F) CDKN2AIP (46.00%).
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Figure 4 The predicted disease-free survival time using the
support vector regression with the 16-gene set.
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nostic factors such as tumor size, advanced stage, inva-
sive depth, lymph node metastasis and differentiation
[51]. An adenovirus that encodes CCL16, when injected
into established nodules significantly delayed tumor growth
[52]. ELF5 can transactivate through the sequences of ETS
transcription factors. ELF5 is localized to human chromo-
some 11p13-15, which is a region that frequently undergoes
loss of heterozygosity in several types of carcinoma,
including those of the breast, kidney and prostate [53].
CDKN2AIP has a known role in tumorigenesis [54]. A
functional role of HDAC5 and HDAC9 in tumor cell
growth in medulloblastoma cell lines has been re-
ported [55]. Three sonic hedgehog effectors, GLI1,
GLI2, and GLI3, regulate the transcription of diverse
genes that are involved in cell growth and cell prolifer-
ation [56]. FOXE1 (TTF-2) is a thyroid-specific tran-
scription factor and a marker in thyroid tumors. The
lung is the most common distant metastatic site for
thyroid carcinomas [57]. MAK is a direct transcrip-
tional target of androgen receptor which plays an im-
portant role in the normal development of prostate as
well as in the progression of prostate cancer [58].
Phylogenetically, TULP3 is the family member that is
most closely related to TUB. TULP3 is detected at
high levels in human RNA from testes, ovaries, the
thyroid, and the spinal chord [59]. TUB encodes a
protein of 561 amino acids that is highly expressed in
a number of tissues examined, including the heart,
brain, ovary, thyroid, spinal chord, and retina and it
maps to chromosome 11p15.4 [60]. The overexpres-
sion of CREG1 reduces cell proliferation in immortal
LFS and cancer cell lines. CREG1 has been identified
as a potent inhibitor of apoptosis [61]. The cooper-
ation of CREG1 and p16 (INK4a) inhibits the expres-
sion of cyclin A and cyclin B by inhibiting promoteractivity, reducing mRNA and protein levels, and these
proteins are required for S-phase entry and G2/M
transition [61,62].
After these putative biomarkers are mapped into the
KEGG pathway database (http://www.genome.jp/kegg/),
several signaling pathways that involve lung cancer me-
tastasis are identified. Mitogen-activated protein kinase
signaling pathway, NF-kappa B signaling pathway, and
immune response IL-1 signaling pathway have been re-
ported in lung cancer metastasis. While regulating pro-
liferation, gene expression, differentiation, mitosis, cell
survival, and apoptosis, the mitogen-activated protein
kinase signaling pathway has long been viewed as an
attractive pathway for anticancer therapies [63]. A higher
nuclear factor-kappa B expression pattern is associated
with more advanced stages of oncogenesis and it will
expand related pathways for invasion and metastasis
in lung cancer [64]. Abnormal IL-1 expression and its
related pathway seem to be related to IKK alpha/beta ac-
tivation, p65 translocation and transcription activity, and
associated to migration of cancer cells [65]. We suggest
that the pathways that are associated with these bio-
markers might play an important role in NSCLC metas-
tasis. This inference offers an opportunity to expand
greatly our knowledge of the expression patterns in
NSCLC. Considering together the expression status of
biomarkers, related signaling pathways, and clinical out-
come will further reveal the roles of the biomarkers in
lung cancer metastasis. An enhanced understanding of
the basic biological mechanisms of NSCLC will likely
facilitate development of improved methods for survival
prediction.
Conclusions
This work proposes a novel methodological approach to
discovering a set of prognostic biomarkers for predicting
the distant metastasis of lung cancer through simultan-
eous utilization of microarray and survival data. The
presented optimization method uses an objective func-
tion to maximize both prediction accuracy and the
disease-free survival area to identify a set of biomarkers.
The additional use of clinical disease-free survival time
can greatly facilitate the discovery of biomarkers and the
prediction of survival time. The proposed method that
combines both microarray and survival data can also
alleviate the problem of overtraining that arises from the
insufficiency of samples. The experimental results herein
show that a combination of multiple biomarkers may
increase diagnostic sensitivity and specificity over those
obtained using individual biomarkers. The proposed
method has high generalizability in the discovery of
prognostic biomarkers not only for the distant metasta-
sis of lung cancer, but also for other cancers using
microarray data and clinical outcomes.
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nostic biomarkers for predicting the distant metastasis
of lung cancer. This work identified a set of 16 prog-
nostic biomarkers that can be used to predict distant
metastasis with high accuracies, a leave-one-out cross-
validation accuracy of 93.59%, an independent test
accuracy of 76.92%, a large predicted disease-free
survival area of 74.81% (close to 73.21% for real sur-
vival area), and a mean survival prediction error of
3.99 months. Closely examining the 16-gene set by
mapping these genes into the KEGG pathway database
reveals some signaling pathways that are involved in
lung cancer metastasis. Future work will incorporate
these findings of signaling pathways with related bio-
markers and clinical outcomes to develop novel methods
for predicting distant metastasis and the survival times of
patients with early-stage NSCLC.
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